Bosentan therapy for pulmonary arterial hypertension

Lewis J. Rubin, David B. Badesch, Robyn J. Barst, Nazzareno Galiè, Carol M. Black, Anne Keogh, Tomas Pulido, Adaani Frost, Sébastien Roux, Isabelle Leconte, Michael Landzberg, Gérald Simonneau

Research output: Contribution to journalArticle

2307 Scopus citations

Abstract

Background: Endothelin-1 is a potent vasoconstrictor and smooth-muscle mitogen. In a preliminary study, the orally administered dual endothelin-receptor antagonist bosentan improved exercise capacity and cardiopulmonary hemodynamics in patients with pulmonary arterial hypertension. The present trial investigated the effect of bosentan on exercise capacity in a larger number of patients and compared two doses. Methods: In this double-blind, placebo-controlled study, we randomly assigned 213 patients with pulmonary arterial hypertension (primary or associated with connective-tissue disease) to receive placebo or to receive 6.25 mg of bosentan twice daily for 4 weeks followed by either of two doses of bosentan (125 or 250 mg twice daily) for a minimum of 12 weeks. The primary end point was the degree of change in exercise capacity. Secondary end points included the change in the Borg dyspnea index, the change in the World Health Organization (WHO) functional class, and the time to clinical worsening. Results: At week 16, patients treated with bosentan had an improved six-minute walking distance; the mean difference between the placebo group and the combined bosentan groups was 44 m (95 percent confidence interval, 21 to 67; P<0.001). Bosentan also improved the Borg dyspnea index and WHO functional class and increased the time to clinical worsening. Conclusions: The endothelin-receptor antagonist bosentan is beneficial in patients with pulmonary arterial hypertension and is well tolerated at a dose of 125 mg twice daily. Endothelin-receptor antagonism with oral bosentan is an effective approach to therapy for pulmonary arterial hypertension.

Original languageEnglish (US)
Pages (from-to)896-903
Number of pages8
JournalNew England Journal of Medicine
Volume346
Issue number12
DOIs
StatePublished - Mar 21 2002

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Bosentan therapy for pulmonary arterial hypertension'. Together they form a unique fingerprint.

Cite this